



GAU 1623

#4
COP
3/16/98

Attorney Docket: NEX61/CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: JANJIC *ET AL.*)
)
SERIAL NO.: 08/897,351)
)
FILED: JULY 21, 1997)
)
TITLE: VASCULAR ENDOTHELIAL)
GROWTH FACTOR (VEGF))
NUCLEIC ACID LIGAND)
COMPLEXES)

EXAMINER: Z. Tomer

ART UNIT: 1634

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies enclosed, which may be material to examination of the above-identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed *within* three months of the filing date of the application or date of entry into the national stage of an international application as set forth in §1.491 or before the mailing date of a first Office Action on the merits under §1.97(b), whichever event occurs last.

No fee is believed to be due in this instance, however the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 22-0277.

37 CFR 1.8

CERTIFICATE OF MAILING


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on February 4, 1998.

Signature:

Name:

Mary Ann Holland
Mary Ann Holland


GROUP 1800
FEB 13 1998
RECEIVED



Additional references have been cited in copending United States Patent Application Serial No. 08/434,465 and 08/464,443, and the Examiner is invited to consider these references. Applicants have reviewed over one hundred references and have determined that the references cited in this PTO Form 1449 are the most relevant. Applicants believe that the other references are cumulative or less relevant than the ones that have been particularly pointed out in the PTO Form 1449.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. The listed patents and publications are believed of interest herein and consideration and citation as of interest by Examiner is respectfully requested.

Respectfully submitted,


Rosemary Kellogg, #39,726
Swanson & Bratschun, L.L.C.
8400 E. Prentice Ave., Suite 200
Englewood, CO 80111
Telephone: (303) 793-3333

cc: V. Appleby

C:\WPDOCS\NEXAGEN\NEX61CIP\ids doc.wpd /mah